Talis Biomedical Corporation reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 0.572 million compared to USD 0.117 million a year ago. Net loss was USD 27.01 million compared to USD 64.47 million a year ago. Basic loss per share from continuing operations was USD 1.01 compared to USD 2.51 a year ago.
For the six months, revenue was USD 3.76 million compared to USD 7.12 million a year ago. Net loss was USD 60.06 million compared to USD 124.96 million a year ago. Basic loss per share from continuing operations was USD 2.26 compared to USD 6.44 a year ago.